Literature DB >> 27765170

Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.

Wickii T Vigneswaran1, Diana Y Kircheva2, Vijayalakshimi Ananthanarayanan3, Sydeaka Watson4, Qudsia Arif3, Amy Durkin Celauro2, Hedy L Kindler5, Aliya N Husain3.   

Abstract

BACKGROUND: Macroscopic complete surgical resection with adjuvant chemotherapy can provide a survival advantage in patients with malignant pleural mesothelioma (MPM). Patients with nonepithelioid histology are largely excluded from such radical operations even though they might benefit. The degree of epithelioid differentiation varies in biphasic histology. We report the outcomes of pleurectomy and decortication and the effect of epithelioid differentiation on overall survival of patients with MPM.
METHODS: This report is based on the outcomes of 144 patients who underwent pleurectomy and decortication at a single institution between 2008 and 2015. The variables assessed were age, gender, histology, and pathologic T and N stage. No patients with pure sarcomatoid histology were included. Two independent pathologists estimated the percentage of epithelioid histology. A Cox regression model was used to identify significant predictors of survival. The Kaplan-Meier method was used to summarize overall and subgroup survival.
RESULTS: Included were 116 men and 28 women with a median age of 69 years (range, 43 to 88 years). The 2-year survival from pleurectomy and decortication was 20%. Median survival overall was 13.34 months and was 20.1 months for the 100% epithelioid subgroup (n = 77), 11.8 months for the 51% to 99% epithelioid subgroup (n = 39), and 6.62 months for the less than 50% epithelioid subgroup (n = 28). The amount of epithelioid differentiation was a significant predictor of survival (p < 0.001). Differences in survival based on the T, but N stage, were not statistically significant.
CONCLUSIONS: The percentage of epithelioid differentiation is an independent predictor of survival in MPM and should be taken into careful consideration when recommending surgical treatment for patients with biphasic MPM.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27765170     DOI: 10.1016/j.athoracsur.2016.08.063

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment.

Authors:  Malgorzata Szolkowska; Katarzyna Blasinska-Przerwa; Magdalena Knetki-Wroblewska; Piotr Rudzinski; Renata Langfort
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma.

Authors:  Wickii T Vigneswaran; Diana Y Kircheva; Adrian E Rodrigues; Sydeaka Watson; Amy Durkin Celauro; Berkley Rose; Hedy L Kindler; Aliya N Husain
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

3.  Pleurectomy and decortication.

Authors:  Tedi Vlahu; Wicki T Vigneswaran
Journal:  Ann Transl Med       Date:  2017-06

Review 4.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.

Authors:  Erica C Nakajima; Paz J Vellanki; Erin Larkins; Somak Chatterjee; Pallavi S Mishra-Kalyani; Youwei Bi; Hisham Qosa; Jiang Liu; Hong Zhao; Missiratch Biable; Lauren Tesh Hotaki; Yuan-Li Shen; Richard Pazdur; Julia A Beaver; Harpreet Singh; Martha Donoghue
Journal:  Clin Cancer Res       Date:  2021-08-30       Impact factor: 13.801

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 7.  The Molecular Basis of Malignant Pleural Mesothelioma.

Authors:  Benjamin Wadowski; Assunta De Rienzo; Raphael Bueno
Journal:  Thorac Surg Clin       Date:  2020-09-12       Impact factor: 1.750

8.  Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.

Authors:  Bertrand Chollet; Julien Guinde; Sophie Laroumagne; Hervé Dutau; Philippe Astoul
Journal:  Thorac Cancer       Date:  2021-05-05       Impact factor: 3.500

9.  Life Expectancy in Pleural and Peritoneal Mesothelioma.

Authors:  Robert Shavelle; Kate Vavra-Musser; Jessica Lee; Jordan Brooks
Journal:  Lung Cancer Int       Date:  2017-01-23

10.  Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma.

Authors:  Guozun Zhang; Dong-Liang Yang; Guoqi Zheng; Yufei Liang
Journal:  Oncol Lett       Date:  2020-04-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.